Pyridine and Pyrazine Derivative for the Treatment of CF
申请人:NOVARTIS AG
公开号:US20190262324A1
公开(公告)日:2019-08-29
The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
On the Structure of PHB (=Poly[(R)-3-hydroxybutanoic Acid]) in Phospholipid Bilayers: Preparation of Trifluoromethyl-Labeled Oligo[(R)-3-hydroxybutanoic Acid] Derivatives
作者:Magnus Rueping、Matthias Albert、Dieter Seebach
DOI:10.1002/hlca.200490222
日期:2004.10
Oligomers of (R)-3-hydroxybutanoate (OHB) have previously been shown to transport cations through lipid bilayers. The ion-transport activity has been attributed to the formation of hydrophobic aggregates or pores, which have been identified by fluorescence-microscopy measurements of membrane-incorporated fluorescence-labeled OHBs. To obtain more information about these aggregates, we describe here